tiprankstipranks
Trending News
More News >
Bio-Rad Laboratories (CH:BUWA)
:BUWA
Switzerland Market

Bio-Rad Laboratories (BUWA) Stock Forecast & Price Target

Compare
0 Followers
See the Price Targets and Ratings of:

BUWA Analyst Ratings

Moderate Buy
5Ratings
Moderate Buy
3 Buy
2 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Bio-Rad
Laboratories
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BUWA Stock 12 Month Forecast

Average Price Target

$266.06
Based on 5 Wall Street analysts offering 12 month price targets for Bio-Rad Laboratories in the last 3 months. The average price target is $266.06 with a high forecast of $324.51 and a low forecast of $223.51. The average price target represents a change from the last price of .
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
Highest Price Target$324.51Average Price Target$266.06Lowest Price Target$223.51
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS
CHF297.74CHF260
Buy
Reiterated
05/02/25
Bio-Rad price target lowered to $310 from $355 at UBSBio-Rad price target lowered to $310 from $355 at UBS
RBC Capital Analyst forecast on CH:BUWA
Conor McNamaraRBC Capital
RBC Capital
CHF343.03CHF328.78
Buy
Reiterated
05/02/25
RBC Capital Keeps Their Buy Rating on Bio-Rad Laboratories (BIO)
Citi
CHF293.55
Buy
Reiterated
05/01/25
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (NASDAQ: PRCT), Intuitive Surgical (NASDAQ: ISRG) and Bio-Rad Laboratories (NYSE: BIO)
Wells Fargo
CHF268.39CHF226.45
Hold
Reiterated
04/17/25
Bio-Rad Labs (BIO) PT Lowered to $270 at Wells FargoWells Fargo analyst Brandon Couillard lowered the price target on Bio-Rad Labs (NYSE: BIO) to $270.00 (from $320.00) while maintaining a Equal Weight rating.
Jefferies
CHF239.03
Hold
Reiterated
03/27/25
Bio-Rad Laboratories (BIO) Receives a Hold from Jefferies
Nephron
CHF327.1
Buy
Upgraded
08/28/24
Nephron upgrades Bio-Rad Labs (BIO) to BuyNephron analyst Jack Meehan upgraded Bio-Rad Labs (NYSE: BIO) from Hold to Buy with a price target of $390.00.
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS
CHF297.74CHF260
Buy
Reiterated
05/02/25
Bio-Rad price target lowered to $310 from $355 at UBSBio-Rad price target lowered to $310 from $355 at UBS
RBC Capital Analyst forecast on CH:BUWA
Conor McNamaraRBC Capital
RBC Capital
CHF343.03CHF328.78
Buy
Reiterated
05/02/25
RBC Capital Keeps Their Buy Rating on Bio-Rad Laboratories (BIO)
Citi
CHF293.55
Buy
Reiterated
05/01/25
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (NASDAQ: PRCT), Intuitive Surgical (NASDAQ: ISRG) and Bio-Rad Laboratories (NYSE: BIO)
Wells Fargo
CHF268.39CHF226.45
Hold
Reiterated
04/17/25
Bio-Rad Labs (BIO) PT Lowered to $270 at Wells FargoWells Fargo analyst Brandon Couillard lowered the price target on Bio-Rad Labs (NYSE: BIO) to $270.00 (from $320.00) while maintaining a Equal Weight rating.
Jefferies
CHF239.03
Hold
Reiterated
03/27/25
Bio-Rad Laboratories (BIO) Receives a Hold from Jefferies
Nephron
CHF327.1
Buy
Upgraded
08/28/24
Nephron upgrades Bio-Rad Labs (BIO) to BuyNephron analyst Jack Meehan upgraded Bio-Rad Labs (NYSE: BIO) from Hold to Buy with a price target of $390.00.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bio-Rad Laboratories

1 Month
xxx
Success Rate
11/19 ratings generated profit
58%
Average Return
-2.12%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 57.89% of your transactions generating a profit, with an average return of -2.12% per trade.
3 Months
xxx
Success Rate
11/19 ratings generated profit
58%
Average Return
+4.07%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.89% of your transactions generating a profit, with an average return of +4.07% per trade.
1 Year
Success Rate
6/16 ratings generated profit
44%
Average Return
+6.65%
reiterated a buy rating last month
Copying Patrick B Donnelly's trades and holding each position for 1 Year would result in 43.75% of your transactions generating a profit, with an average return of +6.65% per trade.
2 Years
xxx
Success Rate
6/16 ratings generated profit
38%
Average Return
-6.14%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 37.50% of your transactions generating a profit, with an average return of -6.14% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BUWA Analyst Recommendation Trends

Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
0
0
0
2
3
Buy
7
5
4
3
2
Hold
2
1
2
3
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
6
6
8
7
In the current month, BUWA has received 5 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. BUWA average Analyst price target in the past 3 months is 266.06.
Each month's total comprises the sum of three months' worth of ratings.

BUWA Financial Forecast

BUWA Earnings Forecast

Next quarter’s earnings estimate for BUWA is $1.50 with a range of $1.34 to $1.61. The previous quarter’s EPS was $2.12. BUWA beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year BUWA has Outperformed its overall industry.
Next quarter’s earnings estimate for BUWA is $1.50 with a range of $1.34 to $1.61. The previous quarter’s EPS was $2.12. BUWA beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year BUWA has Outperformed its overall industry.

BUWA Sales Forecast

Next quarter’s sales forecast for BUWA is $514.83M with a range of $509.17M to $518.41M. The previous quarter’s sales results were $489.64M. BUWA beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year BUWA has Outperformed its overall industry.
Next quarter’s sales forecast for BUWA is $514.83M with a range of $509.17M to $518.41M. The previous quarter’s sales results were $489.64M. BUWA beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year BUWA has Outperformed its overall industry.

BUWA Stock Forecast FAQ

What is CH:BUWA’s average 12-month price target, according to analysts?
Based on analyst ratings, Bio-Rad Laboratories’s 12-month average price target is 266.06.
    What is CH:BUWA’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:BUWA, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Bio-Rad Laboratories a Buy, Sell or Hold?
        Bio-Rad Laboratories has a consensus rating of Moderate Buy, which is based on 3 buy ratings, 2 hold ratings and 0 sell ratings.
          What is Bio-Rad Laboratories’s share price target?
          The average share price target for Bio-Rad Laboratories is 266.06. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $324.51 ,and the lowest forecast is $223.51. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Bio-Rad Laboratories?
            Bio-Rad Laboratories’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.
              How can I buy shares of Bio-Rad Laboratories?
              To buy shares of CH:BUWA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis